ArticleCancers2021
Loss-of-Function Mutations of
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Rare acute myeloid leukemia harboring BCR/ABL1 (P210), AML1-MDS1/EVI1, and AML1/EAP: case report and literature review.Frontiers in oncology · 2026Article
- BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study.Genes, chromosomes & cancer · 2025Article
- Article
- Association of social deprivation with survival in younger adult patients with AML: an Alliance study.Blood advances · 2023Article
- High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.Blood advances · 2022Article
- Case Report: Successful therapy with all-Frontiers in oncology · 2022Article
- From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is characterized by recurrent genetic events. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.